Last reviewed · How we verify
Ribavirin, Peg interferon alfa 2b
Ribavirin and peginterferon alfa-2b work together to inhibit viral replication and enhance immune response against hepatitis C virus.
Ribavirin and peginterferon alfa-2b work together to inhibit viral replication and enhance immune response against hepatitis C virus. Used for Chronic hepatitis C virus infection (genotype-dependent), Hepatitis C in patients with compensated cirrhosis.
At a glance
| Generic name | Ribavirin, Peg interferon alfa 2b |
|---|---|
| Also known as | Peg interferon alfa 2b (Peg Intron) |
| Sponsor | Brooke Army Medical Center |
| Drug class | Antiviral combination therapy |
| Target | HCV RNA-dependent RNA polymerase; interferon-alpha receptor |
| Modality | Small molecule |
| Therapeutic area | Virology/Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase and reduces viral replication. Peginterferon alfa-2b is a long-acting interferon that activates innate immunity and enhances antiviral T-cell responses. Together, they synergistically suppress HCV replication and promote viral clearance.
Approved indications
- Chronic hepatitis C virus infection (genotype-dependent)
- Hepatitis C in patients with compensated cirrhosis
Common side effects
- Anemia
- Fatigue
- Headache
- Myalgia
- Neutropenia
- Thrombocytopenia
- Depression/mood changes
- Insomnia
Key clinical trials
- Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003) (PHASE2)
- Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048) (PHASE1)
- Re-treatment of HCV Following DAA Failure (NA)
- Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection (PHASE3)
- Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection (PHASE3)
- Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection (NA)
- High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV (PHASE3)
- A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ribavirin, Peg interferon alfa 2b CI brief — competitive landscape report
- Ribavirin, Peg interferon alfa 2b updates RSS · CI watch RSS
- Brooke Army Medical Center portfolio CI